Latest stories on AVBP
AVBP Maintained by Guggenheim -- Price Target Lowered to $28.00
GuruFocus42 · neutralanalyst
Guggenheim lowers ArriVent BioPharma stock price target to $28
Investing.com Analyst Ratings34 · bearishanalyst
Arrivent Biopharma Price Target Lowered To 28 From 30 At Guggenheim
The Fly34 · bearishanalyst
ArriVent BioPharma: ARR-217 Gives Us A Reason To Reconsider Our Strong Sell (Rating Upgrade)
Seeking Alpha64 · neutralanalyst
AVBP Maintained by Truist Securities -- Price Target Raised to $24
GuruFocus63 · neutralanalyst
ArriVent BioPharma (AVBP) Reports Q3 Losses with Rising Collaboration Revenue
GuruFocus42 · neutralearnings
ArriVent BioPharma GAAP EPS of -$0.81
Seeking Alpha52 · neutralearnings
ArriVent BioPharma Inc Reports Q3 2026 Results: EPS of -$1.13 Misses Estimates, Revenue Stays at $0 Million
GuruFocus34 · bearishearnings
ArriVent BioPharma (AVBP) Advances Clinical Trials Amid Loss-Making Status and Mixed Insider Activity
GuruFocus44 · neutralgeneral
ArriVent Biopharma reports Q3 EPS (81c), consensus ($1.06)
The Fly34 · bearishearnings
ArriVent BioPharma, Inc. (AVBP) files 8-K
SEC 8-K50 · neutralgeneral
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
StockTitan50 · neutralearnings
AVBP Maintained by Guggenheim -- Price Target Raised to $30.00
GuruFocus61 · neutralanalyst
ArriVent Biopharma price target raised to $30 from $18 at Guggenheim
The Fly64 · neutralanalyst
ArriVent Biopharma price target raised to $21 from $18 at Truist
The Fly63 · neutralanalyst
ArriVent Biopharma price target raised to $25 from $18 at Oppenheimer
The Fly64 · neutralanalyst
ArriVent Biopharma announces initial Phase 1 results for ARR-217
The Fly63 · neutralproduct/pr
At a glance: stocks gapping up premarket
Seeking Alpha63 · neutralgeneral
ArriVent BioPharma, Inc. (AVBP) files 8-K
SEC 8-K50 · neutralgeneral
ArriVent cancer data support ‘best-in-class’ potential, says Clear Street
The Fly64 · neutralanalyst
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
GlobeNewswire64 · neutralproduct/pr
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
Business Insider64 · neutralproduct/pr
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
Business Insider58 · neutralproduct/pr
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
GlobeNewswire58 · neutralproduct/pr